Hormone therapy combined with radiation therapy improves survival rates.

Numerous research studies have recently been released that discuss the effects of hormone therapy combined with radiation therapy in the treatment of prostate cancer. The aim of this article is to provide readers with some useful information on the current standard treatment for prostate cancer. Get more informations of QC Kinetix (Charlotte)

The National Cancer Institute of Canada, the United Kingdom Medical Research Council, and the Southwest Oncology Group in the United States collaborated on a randomised study from 1995 to 2005. The research included 1,205 men with high-risk prostate cancer from the United States, Canada, and the United Kingdom. These men were given either hormone therapy alone or a combination of hormone therapy (with external beam radiation treatment). Patients were followed up on for an average of at least 6 years, and the results show that adding radiation therapy to the combination therapy substantially decreased the risk of death in the study population.

Bolla et al. released a report from an EORTC study in 1997 that showed an improvement in the likelihood of progression-free and overall survival of European patients diagnosed with high-risk prostate cancer (T1-2 and T3-4NO-1MO) tumours. In comparison to patients who received external beam radiation therapy alone, patients who received external beam radiation therapy with adjuvant hormonal therapy for three years had higher survival rates. Additional research from the United States reveals similar findings. According to this report, two to three years of hormone therapy paired with radiotherapy increases patient longevity but comes with a slew of side effects, including impotence, hot flashes, and an increased risk of heart attack.

Horwitz et al indicated in 2008 that radiotherapy combined with prolonged adjuvant hormone therapy for 28 months improved the likelihood of disease-free and disease-specific survival rates in their sample group (RTOG 92-02). The group that received combined therapy had a lower risk of local prostate tumour development, as well as lower rates of biochemical failure. When compared to the radiation therapy community, the combined therapy prevented further metastasis (spread). Overall, patients with a pre-treatment Gleason score of 8-10, no metastasis to the lymph node or pelvis, and a PSA level of 150 ng/ml and below had higher survival rates in this study.

Exposure to the male hormones testosterone is thought to be the cause of prostate cancer. Prostate cancer cells are stimulated to develop as testosterone levels in the body rise. Hormone therapy, also known as Androgen Deprivation Therapy, is administered to patients with prostate cancer as a way of lowering testosterone levels in the body (in which production of male hormones are prevented). External beam radiation is used to directly kill and destroy cancer cells during radiation therapy.